Viewing nowCombinationGlotin Duo Tablet 2.5/850 mg (Linagliptin, Metformin Hydrochloride)
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
NexPharm Korea Co., Ltd.

MFDS item code 202001275 · Approved 2020.02.21 · Insurance code 662504600
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help improve blood sugar control in patients with type 2 diabetes. The combination of linagliptin and metformin helps effectively improve blood glucose levels. This facilitates smoother blood sugar regulation for patients and contributes to the prevention of complications. It greatly assists patients in consistently taking their medication and managing their lifestyle.
The dosage of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Use with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Use with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustments. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Do not Administer to the Following Patients).
This medication can cause a serious side effect known as lactic acidosis; therefore, patients with poor kidney function or issues with heart or liver function should not take it. Additionally, individuals allergic to any of its components, those with type 1 diabetes, acute myocardial infarction, in shock, or pregnant or breastfeeding women should not take this medication. Caution is necessary when used with other diabetes medications or insulin that have a risk of hypoglycemia; if symptoms of hypoglycemia occur, immediate consultation with medical personnel is required. Elderly patients with reduced kidney function or those taking medications that may affect kidney function should regularly undergo kidney function tests while taking this medication. This medication should temporarily be discontinued before and after iodine contrast administration during acute infections, dehydration, or surgical procedures, and can be resumed once kidney function is stabilized. Use of this medication should be done cautiously in patients with liver dysfunction or severe gastrointestinal disorders, and it should be avoided in patients with acute alcohol intoxication or alcoholism. During treatment, attention should be given to the possible occurrence of rare skin disorders such as pancreatitis or bullous pemphigoid, and if symptoms appear, the physician should be notified immediately. Furthermore, this medication may decrease vitamin B12 levels; thus, it is important to regularly check for vitamin B12 deficiency if taken over a long period. Use of this medication is not recommended for women planning to become pregnant, those who are pregnant, or children under 10 years of age. Elderly patients should start with the minimum dose considering reduced kidney function and regular monitoring of kidney function is needed. The impact on driving or operating machinery is not known, so caution is advised. In case of overdose, there is a risk of lactic acidosis; immediate hospital visit for treatment is necessary, and blood dialysis may be required. This medication should be stored out of reach of children, kept away from moisture, and not transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. Additionally, it is important to store it at room temperature between 1 and 30 degrees Celsius to maintain its efficacy.
Bright orange, convex, oval-shaped film-coated tablets
30 tablets/box [(6 tablets/PTP x 5 packs)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
NexPharm Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.